编辑丨王多鱼排版丨水成文抗 PD-1 联合仑伐替尼（lenvatinib，一种多靶点受体酪氨酸激酶抑制剂）治疗在多种肿瘤中均显示出临床疗效，但潜在的免疫学机制尚不清楚。2025 年 1 月 30 ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

浙江大学医学院蔡志坚教授联合浙江农林大学冯华军教授等，在 Cell 子刊 Cell Reports Medicine 上发表了题为： MFGE8 induces anti-PD-1 therapy resistance by promoting ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung ...

The anti-correlation of PD-1 and KLRG1 expression in human tumor infiltrating CD8 T cells suggests the potential for combination therapy ...

A new research paper was published in Oncotarget's Volume 16 on January 20, 2025, titled "Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells." ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed ...

US-based Aethlon Medical has treated the first subject with its Hemopurifier investigational device in its Australian cancer ...